CAR-T collaboration agreement

• AdAlta and its AdCella subsidiary have executed a Development and Collaboration Agreement (“DCA”) to co-develop Shanghai Cell Therapy Group Co Ltd (“SHcell”)’s BZDS1901 for all markets outside greater China • BZDS1901 is a highly differentiated clinical stage, first-in-class armored CAR-T product targeting mesothelin (“MSLN”) with demonstrated complete responses in difficult to treat advanced me